)
Edge11 Sep 2026
Texas Pacific Land Corporation: Keeper of the Permian Basin
Land once granted to a failed 19th-century railroad now generates royalties for Texas Pacific Land Corporation across the Permian Basin.
DexTech Medical
DexTech Medical (DEX) investor relations material
DexTech Medical Q4 25/26 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 25/26 earnings summary31 Aug, 2026
Executive summary
Completed Phase I/IIa clinical study with OsteoDex in relapsed, treatment-resistant multiple myeloma; all patients achieved stable disease, with over 70% maintaining stability post-treatment.
No significant ODX-related adverse events or toxicity observed; primary and secondary study endpoints met.
Ongoing follow-up for patients in highest dose group; final clinical study report postponed until all follow-up data are available.
ODX mechanism of action confirmed in both multiple myeloma and mCRPC, supporting broader oncology applications.
Financial highlights
Net sales were MSEK 0.0 for both the quarter and full year, unchanged from prior periods.
Operating profit for Q4 was MSEK -1.9 (vs. -1.6 prior year); full year operating profit was MSEK -6.6 (vs. -5.3 prior year).
Earnings per share for Q4 was SEK -0.10 (vs. -0.08); full year SEK -0.35 (vs. -0.26).
Cash and cash equivalents at year-end were MSEK 8.6 (vs. 14.7 prior year).
Equity at year-end was MSEK 18.3 (vs. 24.8 prior year); equity ratio 97% (vs. 99%).
Outlook and guidance
Current liquidity is sufficient to finance operations until at least the end of 2028.
Continued focus on out-licensing and partnership opportunities for OsteoDex and pipeline assets.
Ongoing efforts to establish strategic partnerships for further clinical development.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from DexTech Medical
- OsteoDex shows strong clinical promise despite ongoing losses and no sales, with cash lasting to 2028.DEX
Q3 25/26 - OsteoDex myeloma trial shows promise; cash runway extends to 2028 amid ongoing losses.DEXQ2 25/26
- Clinical study progress and strong cash position support continued operations through 2026.DEXQ1 25/26
- 67% of myeloma study patients achieved stable disease, with operations funded through 2026.DEXQ4 24/25
- Losses narrowed, cash reserves remain strong, and clinical progress for OsteoDex advances.DEXQ4 23/24
- Operating loss persists, but promising clinical results and strong cash position support continued R&D.DEXQ1 24/25
- OsteoDex shows promising clinical results as DexTech advances R&D with funding secured to 2026.DEXQ3 24/25
- Promising myeloma study results and strong cash position support DexTech's long-term outlook.DEXQ2 24/25
Next DexTech Medical earnings date
Q1 26/273 Nov, 2027
DexTech Medical
Next DexTech Medical earnings date
Q1 26/273 Nov, 2027
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage